Navigation Links
Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California
Date:3/23/2009

SANTA BARBARA, Calif., March 23 /PRNewswire/ -- Horizon Therapeutics, a privately held biopharmaceutical company today announced that Tim Walbert, president and chief executive officer will present at InsideVenture's Debut Conference, March 25-26, 2009 in Santa Barbara, California. Horizon Therapeutics has been selected from over 170 nominations to be one of 50 top private companies showcased to long-term investors through presentations and 1-on-1 meetings at the invitation only conference. Mr. Walbert will provide an update on the status and upcoming milestones in the development and commercialization of its lead product, HZT-501, a combination high dose ibuprofen and famotidine (Pepcid(R)), including completion and filing of a new drug application later this year. InsideVenture's Selection Boards includes Founders and Partners of leading venture firms including NEA, Venrock, DCM, Domain, Frazier, Clarus, Oak Investment, Aisling, and Versant. Over 130 investors are represented in the selected companies.

"We are honored to support Horizon in their private funding efforts through our online platform and at our debut transactional conference in Santa Barbara," said Mona DeFrawi, Chief Executive Officer of InsideVenture. "InsideVenture was created as a powerful and cost-effective platform to support the companies that grow our economy by facilitating their late stage and pre-IPO financing needs. Structural changes in the capital markets over the past 10 years have blocked the real path to economic growth by challenging the financing of the companies delivering valuable new products, jobs and profits for the world economy. These top 50 companies have invested in innovation, and now InsideVenture is innovating the investment process to support their continued growth"

"Horizon Therapeutics is pleased to use InsideVenture's new financing platform because it provides an efficient means to access and build relationships with a number of high quality private investors" said Tim Walbert, president and CEO of Horizon. "We look forward to introducing investors to our company, to the successful Phase 3 data just announced about HZT-501, and developing important relationships that may help bring this drug to market."

InsideVenture Investor Conference - March 25-26, Santa Barbara, California

Horizon Therapeutics is one of 50 top late-stage private healthcare and technology companies seeking to raise $20-200+M or establish and develop relationships with new investors prior to an eventual IPO. The companies will present their businesses to qualified institutional buyers (QIBs), including mutual fund managers, crossover funds, late stage VC & PE funds and strategic corporate investors. Investors interested in attending the conference may apply for an InsideVenture trial membership; the conference is exclusive to members and by invitation only. The theme of this year's conference is "Investing in Innovation: Innovation in Investing". Investors should contact InsideVenture today to apply for membership and an invitation to the InsideVenture Investor Conference, March 25-26, 2009 in Santa Barbara, California.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit www.horizontherapeutics.com.

About InsideVenture

InsideVenture is an industry sponsored financial marketing utility creating a direct private market platform for institutional and strategic investment in late-stage private companies. InsideVenture's exclusive vetting and membership requirements connect the best late-stage venture-backed companies with revered long-term institutional and strategic investors to facilitate late-stage transactions, IPO participation and aftermarket support. InsideVenture is supported by investment leaders and partners like T. Rowe Price, Wasatch Advisors, SVB Financial Group, NYSE, Alexandria Equities, Intralinks Corporation, New Enterprise Associates, Domain Associates, DCM, Venrock Associates, Versant Ventures, Frazier Healthcare Ventures, Clarus Ventures, and Aisling Capital among others. InsideVenture is based in Menlo Park, California and on the web at www.insideventure.com


'/>"/>
SOURCE Horizon Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Horizon Therapeutics Announces Senior Management Appointments
2. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
3. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
4. Horizon Therapeutics to Present at UBS Global Life Sciences Conference
5. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
6. BioHorizons Global Symposium 2008 Combines Record Attendance with Groundbreaking Technology
7. BioHorizons Announces the Purchase of Implant Logic Systems
8. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
9. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
10. BioHorizons Announces Agreement to Purchase Implant Logic Systems
11. Out beyond the horizon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
(Date:4/19/2017)... Waltham, MA (PRWEB) , ... April 19, 2017 ... ... of a $1.5M Series A-1 financing round. This event adds to several other ... establishment of its’ Executive and Scientific Teams. , ThermaGenix will use ...
(Date:4/19/2017)... 2017  As a Bronze Sponsor of ... ,  Proove® Biosciences, Inc. announces the first-ever ... lifestyle factors to accurately predict prescription opioid abuse. In ... California (USC), the Interventional Pain Institute in ... showing that Proove Opioid Risk® accurately identifies patients ...
(Date:4/18/2017)... ... April 18, 2017 , ... METTLER TOLEDO Process ... concentration levels and vice-versa. , One of the key applications for the measurement ... control or monitoring. The principle of this analytical method is based on pure ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):